AACR-ONT Workshop Washington, DC; April 2017



## Nanopore Sequencing: Methylation and Structural Variant Calling

Winston Timp Department of Biomedical Engineering Johns Hopkins University

## Nanopore: Current Blockage

- Basic concept is similar to Coulter counter – detect and characterize objects based on their blockage of a pore
- Current nanopore work is performed either with ion channel proteins (α-hemolysin, MspA) or fabricated in silicon nitride or graphene membranes.
- Most work focuses on distinguishing what is in the pore based on the duration and level of blockade events





## Nanopore Library Prep



- · Library prep is very similar to methods for short-read sequencing
- For DNA shearing we used Covaris gTubes
- After end-repair and A-tailing, leader adapter with motor protein is ligated
- MinION arrays 512 channels (with 4 pores possible per channel) (shown bottom left from running software); dark green pores are sequencing, light green available, other colors inactive.



## Structural Variation

- Abnormality in large region (50b-3mb) of a chromosome
- Pervasive in cancer 50% of pancreatic ductal adenocarcinoma (PDAC)
- Common in tumor suppressor genes
  such as CDKN2A and SMAD4
- Nanopore sequencing can resolve SVs
  - *But* High coverage desired for heterogeneous samples
  - and size of human genome : 3 Gbps
- We know where SVs tend to occur





4

## Solution-phase Hybridization Capture



#### Agilent SureSelectXT Targeted Sequencing System

- ~90 bps biotinylated RNA probes complementary to target sequence
- Biotin-streptavidin interaction to enrich for the targeted region
- Optimization for long-reads : > 2 kb



# Targeted Capture Optimization

- Trial 1
  - Probe tiling, No empty spaces between probes
  - Target region
    - CDKN2A : 1.5 Mbp
  - Low stringency to allow mismatches
  - Result: 2.28 % on-target
- Trial 2
  - No tiling, average 400 bp space between probes
  - Target regions
    - CDKN2A : 1.5 Mbps
    - SMAD4 : 850 Kbps
  - High stringency to limit off-target capture
  - Consideration of known SV breakpoints
  - PDAC SVs from James Eshleman lab
  - Result: 30 % on-target



# Targeted Sequencing Performance



	Total yield (reads)On-target		On-target percentage	Fold enrichment	Coverage
Illumina NA12878	4.4m	3.7m	85%	641>	K 113X
Nanopore NA12878	107k	32k	30%	353>	K 27X
Nanopore PDAC	56k	20k	26%	332>	K 20X



## Nanopore Structural Variation Detection



- NA12878 (ENCODE Human lymphoblast cell line)
- SVs detected with Sniffles (Schatz lab)
- chr9:21,038,354 21,038,506; 152 bps duplication
- Validated with PacBio data from Genome in a Bottle (Mt. Sinai School of Medicine)



## Nanopore Structural Variation Detection



SMAD4 Structural Variation

- PDAC cell line (Eshleman): Novel, putative SVs detected from PDAC
- chr18: 51,198,535 51,199,143; 600 bps deletion
- Possibly allele-specific SV



## Nanopore Structural Variation Detection



- Large window of coverage; Absence in CDKN2A region
- chr9:21,950,000 -22,436,000; 486 kbps SV
- Homozygous Deletion previously identified with Illumina data
- Sniffles did not detect this SV; No reads covering either breakpoint, unlucky coincidence of probes

## Single Nucleotide Variation Detection



- Nanopolish (Simpson Lab) to improve SNV calling
- Nanopore SNV detection after nanopolish is comparable to Illumina
- Phased SNV analysis is possible with coverage from targeted sequencing

	Illumina	Pre-polish	Post-polish
Avg. Coverage	113	27	27
Correct	1133	2485	947
Total	1211	4138	1017
Precision	94%	60%	93%
Sensitivity	32%	69%	26%

Number of True SNVs: 3587(Eberle, et al. bioRxiv, 2016)



## Single Nucleotide Variation Detection



- Nanopolish (Simpson Lab) to improve SNV calling
- Nanopore SNV detection after nanopolish is comparable to Illumina
- Phased SNV analysis is possible with coverage from targeted sequencing

	Illumina	Pre-polish	Post-polish
Avg. Coverage	113	27	27
Correct	1133	2485	947
Total	1211	4138	1017
Precision	94%	60%	93%
Sensitivity	32%	69%	26%

Number of True SNVs: 3587(Eberle, et al. bioRxiv, 2016)



## Epigenetics: Modern



- Modern Definition of epigenetics involves heritable changes other than genetic sequence, e.g., positive feedback, high order structure, chromatin organization, histone modifications, DNA methylation.
- An analogy to a computer system:
  - DNA Sequence = Hardware
  - User input = Environment
  - Systems Biology = Running programs
  - Epigenetics = RAM



### **Emission Probabilities**

- We measured distributions of current for k-mers from *E. Coli* M.Sssl treated (methylated; green) and untreated (unmethylated; red) samples on two different sets of pores - R7.3 and R9 flowcells.
- Boxplots of AGGTCG and TCGAGT k-mers which both contain CGs show significant differences in current in some cases (AGGTCG R7.3) and little to none in others (TCGAGT R7.3)
- R9 current distribution seem wider in both cases, but gives better discrimination in TCGAGT.



Simpson, Workman, et al. Nature Methods (2017)



#### Nanopore: nanopolish methyltrain



- Standard basecalling does not take into account the 5<sup>th</sup> base mC.
- Using nanopolish, after alignment we return to the signal and asses the logliklihood ratio:  $log(\frac{P(D|S_m)}{P(D|S_r)})$  where  $S_m$  is the probability methylated for a given observable current D and  $S_r$  the probability upmethylated
- probability unmethylated
- We then use 2.5 as the threshold for methylated and -2.5 for unmethylated.

#### NA12878 Methylation



- NA12878 (lymphoblast) gDNA: Illumina WGBS on X-axis (24X coverage) (SRA: GSM1002650) vs. R7.3 (0.02X) or R9 (0.13X) nanopore sequencing.
- Correlation of 0.83 (R7.3) and 0.84 (R9) most gene promoters unmethylated



Simpson, Workman, Nature Methods (2017)

## Methylation at Transcription Start Sites



## **Cancer-Normal Comparison**



		MCF1	0A.MERGED.NAN	IOPORE
MCF10A.MERGED.N	ANOPORE;5461			
MCF10A.MERGED.N/	ANOPORE;5460 •			• • • • • • • • • • • • • • • • • • • •
MCF10A.MERGED.N/	ANOPORE;5459			0.00
MCF10A.MERGED.N	ANOPORE;5458			
MCF1UA.MERGED.N	ANOPORE;5457			
MCF10A.MERGED.N	ANOPORE,5456			
MCE10A MERGED N	ANOPORE:5454			
MCF10A MERGED N	ANOPORE:5453			
MCF10A.MERGED.N	ANOPORE:5452	CO CO CO CO O O O		
MCF10A.MERGED.N	ANOPORE;5451 🖷 💦 🔹 🛑 🧰 🤅			
MCF10A.MERGED.N/	ANOPORE;5450		• • • • •	
MCF10A.MERGED.N/	ANOPORE;5449 🔹 📀 😐			• • • • • • • •
MCF10A.MERGED.N/	ANOPORE;5448 • • • •	• •• •• ••		
MCF10A.MERGED.N	ANOPORE;5447 • • • • • •	(0000000000000000000000000000000000000		
MCF1UA.MERGED.N				
MCF10A.MERGED.N				
MCF10A MERGED N	ANOPORE 5443			
MCF10A.MERGED.N	ANOPORE;5442 • • • • •			
i.				
<b>&gt;</b>		MDAME	3231.MERGED.NA	NOPORE
MDAMB231.MERGED.N/	ANOPORE;4533		• • • • • • • • •	
MDAMB231.MERGED.N/	ANOPORE;4532		• • • • •	
				• • • • •
MDAMB231.MERGED.N	ANOPORE;4531			
MDAMB231.MERGED.N/ MDAMB231.MERGED.N/	ANOPORE;4531 • ANOPORE;4530 •		0 000 0 00 0	
MDAMB231.MERGED.N/ MDAMB231.MERGED.N/ MDAMB231.MERGED.N/	ANOPORE;4531 • ANOPORE;4530 • • • • • • • • • • • • • • • • • • •			0  0  0  0  0  0    00  0  0  0  0  0  0
MDAMB231.MERGED.N/ MDAMB231.MERGED.N/ MDAMB231.MERGED.N/ MDAMB231.MERGED.N/	ANOPORE;4531 ANOPORE;4530 ANOPORE;4529 ANOPORE;4528			
MDAMB231.MERGED.N/ MDAMB231.MERGED.N/ MDAMB231.MERGED.N/ MDAMB231.MERGED.N/ MDAMB231.MERGED.N/	ANOPORE;4531 ANOPORE;4530 ANOPORE;4529 ANOPORE;4528 ANOPORE;4527			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE;4531 ANOPORE;4530 ANOPORE;4529 ANOPORE;4528 ANOPORE;4527			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE;4531 ANOPORE;4530 ANOPORE;4529 ANOPORE;4528 ANOPORE;4527 ANOPORE;4525			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE;4531 ANOPORE;4529 ANOPORE;4529 ANOPORE;4527 ANOPORE;4527 ANOPORE;4526 ANOPORE;4525 ANOPORE;4525			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE,4531 ANOPORE,4530 ANOPORE,4529 ANOPORE,4529 ANOPORE,4527 ANOPORE,4527 ANOPORE,4525 ANOPORE,4525 ANOPORE,4524 ANOPORE,4523			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE;4531 ANOPORE;4530 ANOPORE;4529 ANOPORE;4528 ANOPORE;4527 ANOPORE;4527 ANOPORE;4525 ANOPORE;4524 NNOPORE;4523 ANOPORE;4523			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE,4531 ANOPORE,4529 ANOPORE,4529 ANOPORE,4528 ANOPORE,4527 ANOPORE,4526 ANOPORE,4526 ANOPORE,4524 ANOPORE,4523 ANOPORE,4522			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE;4531 ANOPORE;4530 ANOPORE;4529 ANOPORE;4528 ANOPORE;4527 ANOPORE;4527 ANOPORE;4524 ANOPORE;4523 ANOPORE;4523 ANOPORE;4522 ANOPORE;4521			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE;4531 ANOPORE;4529 ANOPORE;4529 ANOPORE;4528 ANOPORE;4527 ANOPORE;4527 ANOPORE;4527 ANOPORE;4525 ANOPORE;4523 ANOPORE;4521 MOOPORE;4521 ANOPORE;4521			
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE,4531 ANOPORE,4539 ANOPORE,4529 ANOPORE,4529 ANOPORE,4527 ANOPORE,4527 ANOPORE,4525 ANOPORE,4524 ANOPORE,4524 ANOPORE,4524 ANOPORE,4524 ANOPORE,4521 ANOPORE,4519 638150	00 63816	5000 6381700	00 63818000
MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N. MDAMB231.MERGED.N.	ANOPORE,4531 ANOPORE,4539 ANOPORE,4529 ANOPORE,4529 ANOPORE,4527 ANOPORE,4527 ANOPORE,4525 ANOPORE,4524 ANOPORE,4524 ANOPORE,4524 ANOPORE,4524 ANOPORE,4521 ANOPORE,4521 ANOPORE,4520 ANOPORE,4519 638150	00 6381C	3000 6381700 pordinates (Ch	00 63818000 ( <b>F9</b> )

- Reduced representation method:12.5Mb of the genome (3.5-6kb size selection)
- We sequenced this fraction on nanopore and bisulfite Illumina seq
- Long reads measure *phased* methylation



Is Methylated

FALSE

TRUE

## Haplotype-Phased Methylation

nanopolish has experimental support for phasing methylation patterns





## Haplotype-Phased Methylation

nanopolish has experimental support for phasing methylation patterns





## Next Steps



- Expand to non 5-methylcytosine methylation
  - Strong signal for N6methyladenine
- Apply to clinical samples
- Exogenous labeling of DNA and readout





## Acknowledgments



JOHNS HOPKINS WHITING SCHOOL

of ENGINEERING



- Winston Timp
- Rachael Workman
- Stephanie Hao
- Yunfan Fan
- Isac Lee



#### **Agilent Technologies**

#### **Agilent Technologies**

Josh Wang, PhD Jonathan Levine, PhD



- Eshleman Lab Johns Hopkins School of Medicine
- James Eshleman, MD, PhD
- Alexis Norris, PhD



- Ontario Institute for Cancer Research
- Jared Simpson, PhD
- P.C. Zuzarte, PhD
- Matei David, PhD
- L. J. Dursi, PhD



### Extra Slides

